A prospective study of Chlamydia pneumoniae infection and risk of MS in two US cohorts

Neurology

Volumn 62, Issue 10, 2004, Pages 1799-1803

  Munger, K L ^a   DeLorenze, G N ^b   Levin, L I ^c   Rubertone, M V ^d   Vogelman, J H ^e   Peck, C A ^f   Peeling, R W ^g   Orentreich, N ^e   Ascherio, Alberto ^a,h  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b DIVISION OF RESEARCH   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d Army Medical Surveillance Activity   (United States)

^e Orentreich Foundation for the Advancement of Science Inc   (United States)

^f US Army Physical Disability Agency   (United States)

^g PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN G;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CASE CONTROL STUDY; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 2442657790     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000125193.58601.2C     Document Type: Article

References (23)

1. Sriram S, Mitchell W, Stratton C. Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS. Neurology 1998;50:571-572.
2. Sriram S, Stratton CW, Yao S, et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999;46:6-14.
3. Layh-Schmitt G, Bendl C, Hildt U, et al. Evidence for infection with Chlamydia pneumoniae in a subgroup of patients with multiple sclerosis. Ann Neurol 2000;47:652-655.
4. Kaufman M, Gaydos CA, Sriram S, Boman J, Tondella ML, Norton HJ. Is Chlamydia pneumoniae found in spinal fluid samples from multiple sclerosis patients? Conflicting results. Mult Scler 2002;8:289-294.
5. Yao SY, Stratton CW, Mitchell WM, Sriram S. CSF oligoclonal bands in MS include antibodies against Chlamydophila antigens. Neurology 2001;56:1168-1176.
6. Munger KL, Peeling RW, Hernan MA, et al. Infection with Chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology 2003;14:141-147.
7. Boman J, Roblin PM, Sundstrom P, Sandstrom M, Hammerschlag MR. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology 2000;54:265.
8. Hammerschlag MR, Ke Z, Lu F, Roblin P, Boman J, Kalman B. Is Chlamydia pneumoniae present in brain lesions of patients with multiple sclerosis? J Clin Microbiol 2000;38:4274-4276.
9. Krametter D, Niederwieser G, Berghold A, et al. Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker. Mult Scler 2001;7:13-18.
10. Rubertone MY, Brundage JF. The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health 2002;92:1900-1904.
11. Levin LI, Munger KL, Rubertone MV, et al. Multiple sclerosis and Epstein-Barr virus. JAMA 2003;289:1533-1536.
12. Friedman GD, Blaner WS, Goodman DS, et al. Serum retinol and retinol-binding protein levels do not predict subsequent lung cancer. Am J Epidemiol 1986;123:781-789.
13. Poser CM. Onset symptoms of multiple sclerosis (letter). J Neurol Neurosurg Psychiatry 1995;58:253-254.
14. Wang S. Serology for Chlamydia pneumoniae (TWAR). In: Allegra L, Blasi F, eds. Chlamydia pneumoniae, the lung and the heart. Milan: Springer-Verlag, 1999;16-23.
15. Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001;33:492-503.
16. Grayston JT, Campbell LA, Kuo C-C, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990;161:618-625.
17. Tompkins LS, Schachter J, Boman J, et al. Collaborative multidisciplinary workshop report: detection, culture, serology, and antimicrobial susceptibility testing of Chlamydia pneumoniae. J Infect Dis 2000;181 Suppl 3:S460-461.
18. Bashir K, Kaslow RA. Chlamydia pneumoniae and multiple sclerosis: the latest etiologic candidate. Epidemiology 2003;14:133-134.
19. Hao Q, Miyashita N, Matsui M, Wang HY, Matsushima T, Saida T. Chlamydia pneumoniae infection associated with enhanced MRI spinal lesions in multiple sclerosis. Mult Scler 2002;8:436-440.
20. Derfuss T, Gurkov R, Bergh FT, et al. Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. Brain 2001;124(Pt 7):1325-1335.
21. Grimaldi LM, Pincherle A, Martinelli-Boneschi F, et al. An MRI study of Chlamydia pneumoniae infection in Italian multiple sclerosis patients. Mult Scler 2003;9:467-471.
22. Hintzen RQ, Verkooyen RP, Hop W, van der Zwaan E, van Doorn PA, Buljevac D. Chlamydia pneumoniae infections are associated with increased disease activity in multiple sclerosis. Neurology 2003;60(5 S1):A60-A61.
23. Du C, Yao SY, Ljunggren-Rose A, Sriram S. Chlamydia pneumoniae infection of the central nervous system worsens experimental allergic encephalitis. J Exp Med 2002;196:1639-1644.